AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21297553
Drug: Intensified dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified dosing (ID) regimen of enteric-coated mycophenolate sodium (EC-MPS) (2880 mg/day for days 0-14, 2160 mg/day for days 15-42, followed by 1440 mg/day)
Trial: 21297553
Drug: Standard dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dosing (SD) regimen of enteric-coated mycophenolate sodium (EC-MPS) (1440 mg/day)
Trial: 21297553
Drug: Intensified dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified dosing (ID) regimen of enteric-coated mycophenolate sodium (EC-MPS)
Trial: 21297553
Drug: Standard dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dosing (SD) regimen of enteric-coated mycophenolate sodium (EC-MPS)
Trial: 19805674
Drug: Alemtuzumab 30
RxNorm normalized name: alemtuzumab 30 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alemtuzumab 30 mg IV three times weekly for up to 3 months and pentostatin 4 mg/m2 IV weekly for 4 weeks followed by alternate weekly administration for up to 6 months
Trial: 19805674
Drug: Prophylactic antibiotics
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic antibiotics including antiviral, antifungal, and antibacterial agents
Trial: 16939066
Drug: Enteric-coated mycophenolate
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enteric-coated mycophenolate sodium (EC-MPS, myfortic) 720 mg b.i.d. with cyclosporine microemulsion and corticosteroids
Trial: 11374602
Drug: High-dose aprotinin
RxNorm normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-dose aprotinin (2 x 10(6) KIU at induction, continuous infusion of 1 x 10(6) KIU/h, 1 x 10(6) KIU before reperfusion; n = 24)
Trial: 11374602
Drug: Regular-dose aprotinin
RxNorm normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Regular-dose aprotinin (2 x 10(6) KIU at induction, continuous infusion of 0.5 x 10(6) KIU/h; n = 21)
Trial: 1414239
Drug: Oxiracetam (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxiracetam (800 mg tablet), twice daily for 12 weeks
Trial: 30316960
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (sham intervention of similar dose)
Trial: 29386172
Drug: Remote Collaborative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remote Collaborative Depression Care (RCDC), N=65, 3-month treatment with continuous remote supervision by psychiatrists through shared electronic health records (SEHR) and phone monitoring.
Trial: 22464674
Drug: Oral bacterial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral bacterial lysate (heat‐killed Escherichia coli and Enterococcus faecalis) from week 5 until the end of month 7
Trial: 20383345
Drug: Prulifloxacin 600
RxNorm normalized name: Orbifloxacin
DrugBank: Orbifloxacin (DB11443)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prulifloxacin 600 mg once daily for 14 days
Trial: 20383345
Drug: Doxycycline 100
RxNorm normalized name: doxycycline 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline 100 mg orally twice daily for 21 days
Trial: 15750458
Drug: Oseltamivir (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oseltamivir (2 mg/kg)
Trial: 12427146
Drug: N-acetylcysteine (NAC),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC), 1200 mg one hour before angiography and a second dose 3 hours after; IV hydration
Trial: 1399301
Drug: wide spectrum
RxNorm normalized name: Sentinel Spectrum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: wide spectrum intravenous antibiotics and suction and debridement
Trial: 3160322
Drug: Cefazolin sodium
RxNorm normalized name: Cefazolin Sodium
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefazolin sodium (20 mg/kg)
Trial: 3160322
Drug: Cefoxitin sodium
RxNorm normalized name: Cefoxitin Sodium
DrugBank: Cefoxitin (DB01331)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefoxitin sodium (30 mg/kg)
Trial: 18020888
Drug: No hormonal
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No hormonal replacement therapy
Trial: 15516696
Drug: Telmisartan (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan (80 mg daily)
Trial: 9516894
Drug: Montelukast 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast 100 mg once daily
Trial: 8458257
Drug: Trimebutine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimebutine (200 mg/day per os) for one month
Trial: 25052238
Drug: Baclofen 10
RxNorm normalized name: baclofen 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baclofen 10 mg 3 times daily for 5 days
Trial: 25052238
Drug: Placebo 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 10 mg 3 times daily for 5 days
Trial: 20395869
Drug: Pravastatin 40
RxNorm normalized name: pravastatin 40 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 40 mg every day for 4 days
Trial: 20395869
Drug: Raltegravir 400
RxNorm normalized name: raltegravir 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltegravir 400 mg twice a day for 4 days
Trial: 20395869
Drug: Pravastatin 40
RxNorm normalized name: pravastatin 40 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 40 mg every day + Raltegravir 400 mg twice a day for 4 days
Trial: 18315579
Drug: Clarithromycin 1
RxNorm normalized name: clarithromycin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 1 g o.d. for 3 months
Trial: 18315579
Drug: Clarithromycin 1
RxNorm normalized name: clarithromycin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 1 g o.d. for 1 month
Trial: 15737906
Drug: Urethral dose
RxNorm normalized name: Product manufactured as urethral dose form
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urethral dose <150% minimum peripheral dose (mPD)
Trial: 15737906
Drug: Urethral dose
RxNorm normalized name: Product manufactured as urethral dose form
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urethral dose 150% minimum peripheral dose (mPD)
Trial: 7004470
Drug: Propranolol 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 0.15 mg per kg body weight i.v.
Trial: 31155472
Drug: Intravitreal ranibizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal ranibizumab (IVR) injections
Trial: 31454045
Drug: Tandem transplant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tandem transplant with thiotepa/cyclophosphamide followed by dose-reduced carboplatin/etoposide/melphalan (n = 176)
Trial: 28303328
Drug: Palmitoyl-KVK-L-ascorbic acid
RxNorm normalized name: palmitoyl collagen acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palmitoyl-KVK-L-ascorbic acid cream
Trial: 28303328
Drug: Palmitoyl-KVK-L-ascorbic acid
RxNorm normalized name: palmitoyl collagen acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palmitoyl-KVK-L-ascorbic acid (20 μg/mL)
Trial: 21537051
Drug: Combination vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination vitamin E (800 U), soy (40 g), and selenium (200 μg)
Trial: 17578197
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy with alpha-adrenoblockers
Trial: 17578197
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with antibacterial drugs
Trial: 15152897
Drug: sustained-release melatonin
RxNorm normalized name: melatonin Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sustained-release melatonin 2 mg
Trial: 8005275
Drug: Progesterone (P)
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Progesterone (P) 50 mg/d
Trial: 8005275
Drug: Progesterone (P)
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Progesterone (P) 50 mg/d + Estrogen (E2) valerate 2 mg/d
Trial: 2510272
Drug: Cimetidine 400
RxNorm normalized name: cimetidine 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 400 mg b.d.
Trial: 790546
Drug: 300 mg/day
RxNorm normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg/day of ketoprofen
Trial: 790546
Drug: 600 mg/day
RxNorm normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg/day of phenylbutazone
Trial: 790546
Drug: Both drugs
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both drugs (ketoprofen and phenylbutazone)
Trial: 31491602
Drug: Radial approach
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radial approach and bivalirudin treatment
Trial: 27878824
Drug: Atraumatic restorative
RxNorm normalized name: DRESSING,RESTORE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atraumatic restorative treatment (ART)-based approach
Trial: 20637053
Drug: 1,3-β-d-glucan-containing nutritional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,3-β-d-glucan-containing nutritional supplement
Trial: 18974448
Drug: Unipedal standing
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unipedal standing therapy (3 times a day for an unspecified duration)
Trial: 18974448
Drug: Unipedal standing
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unipedal standing therapy
Trial: 16550299
Drug: Alendronate (ALN)
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alendronate (ALN) 70 mg weekly
Trial: 12741307
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (LMWH) - enoxaparine (100 IU/kg twice daily) for an average duration of 13 days, followed by fluindione starting on the fifth day.
Trial: 8869692
Drug: Cyclosporin A
RxNorm normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin A (2.5 mg/kg/day)
Trial: 1512185
Drug: Alcohol treatment
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol treatment (maximal BALs of 0.05 or 0.10)
Trial: 1512185
Drug: Alcohol treatment
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol treatment (ascending BALs)
Trial: 1512185
Drug: Alcohol treatment
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol treatment (maximal intoxication)
Trial: 6861866
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg lorcainide tablets taken at 0, 12 and 24 h
Trial: 6861866
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg lorcainide tablets taken at 0, 1, 12 and 24 h
Trial: 6861866
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg lorcainide tablets taken at 0, 2, 12 and 24 h
Trial: 26140541
Drug: Lipid (dairy-cream)
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid (dairy-cream)
Trial: 17900408
Drug: Melatonin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (2 mg/day)
Trial: 17900408
Drug: Rilmazafone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rilmazafone (2 mg/day)
Trial: 11525272
Drug: Raloxifene hydrochloride,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene hydrochloride, 60 mg/d for 6 months
Trial: 9801723
Drug: Dual Focus
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual Focus Schema Therapy (manual-guided individual cognitive-behavioral therapy) for 24 weeks
Trial: 9801723
Drug: 12-Step Drug
RxNorm normalized name: STEP 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-Step Drug Counseling
Trial: 7949701
Drug: Zygapophysial joint
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zygapophysial joint injections or blocks of the medial branches of the dorsal ramus with lignocaine
Trial: 29564750
Drug: Topical dressing
RxNorm normalized name: Gelocast, topical dressing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical dressing formulated with 0.1% P1G10
Trial: 24326198
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (traditional orthodontic treatment without photobiomodulation)
Trial: 18163011
Drug: Levothyroxine (L‐T4)
RxNorm normalized name: L-T4
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Levothyroxine (L‐T4) (n = 20)
Trial: 11986705
Drug: Type B
RxNorm normalized name: HLA type B IgG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type B inactivated vaccine against HFRS
Trial: 7801390
Drug: Active laser
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active laser treatment (40 mW in 60 sec per cm tender tibia edge)
Trial: 3294038
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) controlled-release tablets, 300 mg b.i.d.
Trial: 27289174
Drug: Haemopoietic stem-cell
RxNorm normalized name: Longeveron mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haemopoietic stem-cell gene therapy (HSC-GT) with autologous HSCs transduced with a lentiviral vector encoding ARSA cDNA after busulfan conditioning
Trial: 24715381
Drug: Tamoxifen treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen treatment for 2-5 years
Trial: 19934404
Drug: Selective COX‐2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective COX‐2 inhibitor (celecoxib; 200 mg/dose, 600 mg total)
Trial: 18385262
Drug: Nasal instillation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal instillation of midazolam (0.2 mg kg(‐1))
Trial: 18385262
Drug: Nebulized administration
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized administration of midazolam (0.2 mg kg(‐1))
Trial: 16780390
Drug: simvastatin 5
RxNorm normalized name: simvastatin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: simvastatin 5 mg/day (n = 10)
Trial: 16780390
Drug: losartan 50
RxNorm normalized name: LOSARTAN 50MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: losartan 50 mg/day (n = 9)
Trial: 16780390
Drug: control (usual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: control (usual treatment; n = 8)
Trial: 24432670
Drug: PMC therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PMC therapy combined with LFJC (Langchuang Fuzheng Jiedu Capsule)
Trial: 24432670
Drug: PMC therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PMC therapy combined with LFJC
Trial: 21596725
Drug: CEBM (Centre
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEBM (Centre for Evidence‐Based Medicine, Oxford)
Trial: 12457031
Drug: Granisetron (GRN)
RxNorm normalized name: Granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Granisetron (GRN) alone (3 mg/patient)
Trial: 12457031
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (CCT) with Granisetron (GRN), Methylprednisolone (MPD) (250 mg/patient), and Droperidol (DRP) (0.5 ml/patient)
Trial: 8363290
Drug: Tropicamide alone
RxNorm normalized name: Tropicamide
DrugBank: Tropicamide (DB00809)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tropicamide alone or in combination with phenylephrine
Trial: 3092196
Drug: hGRF 100,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hGRF 100, 300, and 600 micrograms (subcutaneous administration)
Trial: 3092196
Drug: hGRF doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hGRF doses above 80 micrograms
Trial: 3092196
Drug: hGRF doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hGRF doses less than 80 micrograms
Trial: 27809592
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Tamsulosin and Solifenacin
Trial: 25944940
Drug: Conventional oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional oxygen therapy (non-rebreathing face mask)
Trial: 20024753
Drug: Directly Administered
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Directly Administered Antiretroviral Therapy (DAART)
Trial: 17151339
Drug: 20 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/kg rhGAA
Trial: 17151339
Drug: 40 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/kg rhGAA
Trial: 17151339
Drug: rhGAA (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhGAA (both doses)
Trial: 15096906
Drug: Valsartan 160
RxNorm normalized name: valsartan 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 160 mg or Amlodipine 10 mg (after up-titration)
Trial: 15096906
Drug: Valsartan +
RxNorm normalized name: Valsartan
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Valsartan + Hydrochlorothiazide (12.5 mg)
Trial: 15096906
Drug: Amlodipine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine + Hydrochlorothiazide (12.5 mg)
Trial: 11429364
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg amantadine IV in 500 mL saline
Trial: 11429364
Drug: 500 mL
RxNorm normalized name: TPN Bag 500 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mL saline IV (Control group)
Trial: 9554288
Drug: OMV vaccine
RxNorm normalized name: meningococcal group B vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OMV vaccine with aluminium hydroxide and serogroup C-polysaccharide (C-ps)
Trial: 9554288
Drug: OMV vaccine
RxNorm normalized name: meningococcal group B vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OMV vaccine without aluminium hydroxide
Trial: 9554288
Drug: OMV vaccine
RxNorm normalized name: meningococcal group B vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OMV vaccine adsorbed to aluminium hydroxide
Trial: 8052950
Drug: Low level
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low level energy infra-red laser irradiation (4 minutes, total dose = 1J)
Trial: 31125171
Drug: Dermocosmetic treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dermocosmetic treatments
Trial: 23812462
Drug: Daily vaginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily vaginal dilator use from postoperative weeks 4 through 8
Trial: 19583607
Drug: Standard coronary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard coronary bypass surgery without any additional medication (Control)
Trial: 15630352
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy for high-risk patients
Trial: 15630352
Drug: Palliative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palliative chemotherapy for metastatic disease
Trial: 15630352
Drug: Multimodality treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodality treatment options (operation, chemotherapy, radiotherapy, biology therapy)
Trial: 10037207
Drug: Prednisone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (50 mg BID for 3 days)
Trial: 8746921
Drug: Daily dosing
RxNorm normalized name: Osmolex 322 MG Daily Dosing Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dosing of 8 mg sublingual buprenorphine
Trial: 8746921
Drug: Alternate-day dosing
RxNorm normalized name: Alternaria alternata
DrugBank: Alternaria alternata (DB10424)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternate-day dosing of 8 mg sublingual buprenorphine
Trial: 2286597
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg i.v. ofloxacin per day
Trial: 2286597
Drug: 3 x
RxNorm normalized name: Xenon (133 xe)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 x 4000 mg piperacillin per day
Trial: 7018639
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg of glucagon intravenously
Trial: 30180880
Drug: Conversational agent
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conversational agent with high self-awareness
Trial: 30180880
Drug: Conversational agent
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conversational agent with low self-awareness
Trial: 22724387
Drug: Other anti-epileptic
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other anti-epileptic drugs
Trial: 16238275
Drug: 12 mg
RxNorm normalized name: pectin 12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mg of Dexamethasone every 12 hours for two doses (Group C, n=10)